Page 3 - Peter Lio News Today

Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data.

Lisa Swanson, MD, PhD, reviews the indications for ruxolitinib, abrocitinib, and upadacitinib, as well as the clinical trial data on efficacy of these JAK inhibitors when treating AD.

Expert dermatologists discuss the factors that differentiate JAK inhibitors from other AD therapies, highlighting itch scores as they relate to quality of life.

Alexandra Golant, MD; Christopher Bunick, MD, PhD; and Peter Lio, MD, comment on how targeting the JAK-STAT (signal transducer and activator of transcription) pathway with JAK inhibitors plays a role in managing AD.

Peter Lio, MD, and Lisa Swanson, MD, PhD, provide an overview of Janus Kinase (JAK) inhibitors, their pathophysiology, and their mechanism of action in the treatment of atopic dermatitis (AD).

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, gives a preview of his session on mild to moderate atopic dermatitis (AD) in skin of color.

Researchers say gut health may be connected to the development of the skin condition eczema in infants

Learn more about living with moderate-to-severe eczema and a potential treatment option.

In addition to breakage and frizz, your wet hair and pillow are a hotbed for fungus.

A doctor diagnosed Megan Crome with topical steroid withdrawal in March — two years after she self-diagnosed with the help of a Facebook group.